Investigational SGLT2 Inhibitor Submitted as Monotherapy and in Fixed-Dose Combinations with JANUVIA ®(sitagliptin) or Metformin
Merck and Pfizer Announce U.S. FDA and EMA Filing Acceptances of Three Marketing Applications for Ertugliflozin-Containing Medicines for Adults with Type 2 Diabetes | Merck Newsroom Home
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.